Overview Fesoterodine "add-on" Male Overactive Bladder Study Status: Completed Trial end date: 2009-02-01 Target enrollment: Participant gender: Summary To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment. Phase: Phase 3 Details Lead Sponsor: PfizerTreatments: Fesoterodine